Skip to content
Company Analysis

Bristol-Myers Squibb Company BMY

A comprehensive view of key metrics, scores, and financial health for Bristol-Myers Squibb Company

Overview of Bristol-Myers Squibb Company

BMY NYQ
Healthcare Drug Manufacturers - General Large Cap
Bristol-Myers Squibb Company (BMY), is a Large Cap company, in the Drug Manufacturers - General industry, last closed at $59.08, about 9.0% overvalued vs fair value, -1.5% 1Y return, placing in the top 25% of its sector.
$59.08
0.22%
As of March 13, 2026
Previous close • Vol 90d: 26.4%
52-Week Range
Market Cap
$120.31B
Enterprise Value
$157.24B
Overall Score
Scores locked

Create a free account to see overall and pillar scores for Bristol-Myers Squibb Company.

Top Beats
No strong beats yet

Quick Facts

Website https://www.bms.com
HQ Princeton, NJ
Employees 32,500
Fiscal year Dec 31

Next Events

Earnings Apr 30 Call: Apr 30
Dividend May 1 Ex-div: Apr 2

Fair Value Snapshot

Bear Base Bull
$49
$54
$59
Current: $59.08 -9% vs base

Engine Room Money Flow™

Large Cap

Pharmaceutical / Mature Biotech - Where revenue goes and how value is created

Flow Steps
Total Revenue
$48.2B
-0.2%%
Gross Profit
$34.3B
-0.2%%
R&D Expense
$10.0B
-10.8%%
Operating Income (EBIT)
$11.2B
274.4%%
Money Flow Bridge
Flow Direction: Money moves from left to right
Components: Breakdown shows composition of each stage
Industry-Specific: Pharmaceutical / Mature Biotech

Quality & Reliability Indicators

Cash Conversion
126.2%
Excellent

Strong cash conversion - profit becomes cash

Locked Metric
-
Premium
Locked Metric
-
Premium
Locked Metric
-
Premium
Locked Metric
-
Premium

Owner's Pocket - Capital Allocation

Total Returned to Shareholders

Combined dividends, buybacks, and debt reduction

$5.0B
39.3% of FCF

Where It Leaks

Cash Flow Health some concerns
Moderate efficiency issues detected. Review active leaks below for improvement areas.
1
Active Leaks
0/1
Improving
0
High Impact
0
Critical
Moat Analysis Corporate Default

Competitive Advantage Assessment

Evaluating Bristol-Myers Squibb Company's durable competitive advantages across 6 defense dimensions

Overall Moat Strength
61
/100
Moderate
Scores based on quantitative metrics and qualitative factors

Upgrade to unlock interactive defense details

Premium access

Unlock full defense analysis

Get key signals, strengths, and risks for every moat dimension.

Upgrade to Premium Unlock all moat defenses and evidence.

Pricing Power

Moderate
51
Premium
Unlock full defense details

See key signals plus strengths and risks for this moat dimension.

Upgrade for full defense analysis Premium-only evidence and insights.
For informational purposes only. Not investment advice.

Trade-Off Ledger™

Where management spends the performance budget - Growth, Profitability, or Safety

Generic Industrial / Default vs Industry Peers 100% Coverage
Trade-Off Triangle Visualization A ternary plot showing BMY's balance between Growth (26.9%), Profitability (36.6%), and Safety (36.6%). Growth 27% Safety 37% Profitability 37%

Click axes to expand details. Marker shows current allocation.

3-Year Trend Analysis Locked
Upgrade to unlock the full 3-year trend analysis and deltas.

Growth

44th percentile vs peers
44
Key Signals
EPS Growth YoY 1.78 89p EPS CAGR 3Y 5.5% 62p Rev Growth YoY -0.2% 26p Revenue CAGR 3Y 1.5% 26p TSR -0.2% 26p
Strengths
  • Eps Growth Yoy in top 20% of peers (1.78, 89th percentile)
  • D/E Ratio in top 20% of peers (2.55, 85th percentile)
  • Superior capital returns - 3 return metrics above peer median
Risks

No significant risks identified for this axis.

Profitability

60th percentile vs peers
60
Key Signals
Strengths
Risks
Premium
Unlock full Profitability drilldowns

See the signal-level drivers and insights behind this axis. Upgrade to reveal the full Trade-Off Ledger.

Upgrade Now

Safety

60th percentile vs peers
60
Key Signals
Strengths
Safety drilldowns are available to premium members.

Two Futures

Scenario-based fair value ranges for Bristol-Myers Squibb Company.

Loading valuation model...
Unable to Compute Fair Value

This company cannot be valued using standard models.

What this means: The Scenario Theatre requires financial data (revenue, cash flow, shares outstanding) to calculate fair value estimates. This data may be unavailable for:

  • Recently listed companies (IPOs, SPACs)
  • Shell companies or holding companies
  • Companies that haven't filed recent financials
  • Foreign companies with limited data coverage
X.X%
X%XX%
X.X%
-XX%XX%
XX.X%
-XX%XX%
Adjust the sliders above to explore different valuation scenarios.
Unlock Premium
Reveal the full Scenario Theatre
See live sliders, narratives, and full Bear/Base/Bull outcomes.
Upgrade Now
Bear
-
- - -
- upside
-
Base
$53.79
- - -
-9.0% vs current
Snapshot base estimate
Bull
-
- - -
- upside
-
Fair Value Range Current: $-
$- $- $-
Actions & Info